M Stacy

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint The economic and quality of life burden associated with Parkinson's disease: a focus on symptoms
    Deborah F Boland
    Movement Disorders Center, Division of Neurology, Department of Medicine, Duke University, Durham, NC 27705, USA
    Am J Manag Care 18:S168-75. 2012
  2. pmc Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE)
    Joseph Jankovic
    Baylor College of Medicine, Department of Neurology, Houston, TX, USA
    BMC Neurol 11:140. 2011
  3. pmc Pesticide exposure and risk of Parkinson's disease: a family-based case-control study
    Dana B Hancock
    Center for Human Genetics, Duke University Medical Center, Durham, NC, USA
    BMC Neurol 8:6. 2008
  4. doi request reprint The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson's disease
    Mark Stacy
    Division of Neurology, Duke University Medical School, 932 Morreene Road, MS 3333, Durham, NC 27705, USA
    J Neural Transm 117:837-46. 2010
  5. doi request reprint A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
    M Stacy
    Division of Neurology, Duke University Medical Center, Durham, NC 27705, USA
    Neurology 70:2233-40. 2008
  6. doi request reprint Nonmotor symptoms in Parkinson's disease
    Mark Stacy
    Department of Neurology, Duke University Medical Center, Durham, North Carolina 27705, USA
    Int J Neurosci 121:9-17. 2011
  7. ncbi request reprint Apomorphine for the acute treatment of "off" episodes in Parkinson's disease
    Mark Stacy
    Division of Neurology, Duke University, 932 Morreene Road, MS 3333, Durham, NC27705, USA
    Parkinsonism Relat Disord 14:85-92. 2008
  8. ncbi request reprint Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment
    Mark Stacy
    Duke University Medical Center, 932 Morreene Road, Durham, NC 27705, USA
    Mov Disord 20:726-33. 2005
  9. ncbi request reprint End-of-dose wearing off in Parkinson disease: a 9-question survey assessment
    Mark Stacy
    Division of Neurology, Duke University Medical School, Durham, North Carolina 27705, USA
    Clin Neuropharmacol 29:312-21. 2006
  10. ncbi request reprint Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson's disease
    M Stacy
    Duke University Medical Center, Durham, North Carolina 27705, USA
    J Neural Transm 114:211-7. 2007

Detail Information

Publications35

  1. ncbi request reprint The economic and quality of life burden associated with Parkinson's disease: a focus on symptoms
    Deborah F Boland
    Movement Disorders Center, Division of Neurology, Department of Medicine, Duke University, Durham, NC 27705, USA
    Am J Manag Care 18:S168-75. 2012
    ..This may have a measurable impact by improving QoL measures for both the patient and caregivers...
  2. pmc Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE)
    Joseph Jankovic
    Baylor College of Medicine, Department of Neurology, Houston, TX, USA
    BMC Neurol 11:140. 2011
    ..Irvine, CA, USA). Methods and baseline demographics from an interim analysis are provided...
  3. pmc Pesticide exposure and risk of Parkinson's disease: a family-based case-control study
    Dana B Hancock
    Center for Human Genetics, Duke University Medical Center, Durham, NC, USA
    BMC Neurol 8:6. 2008
    ..Pesticides and correlated lifestyle factors (e.g., exposure to well-water and farming) are repeatedly reported risk factors for Parkinson's disease (PD), but few family-based studies have examined these relationships...
  4. doi request reprint The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson's disease
    Mark Stacy
    Division of Neurology, Duke University Medical School, 932 Morreene Road, MS 3333, Durham, NC 27705, USA
    J Neural Transm 117:837-46. 2010
    ..The manuscript also provides an overview of the motor and non-motor signs of wearing-off and highlights the available treatment strategies for managing this potentially debilitating phenomenon...
  5. doi request reprint A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
    M Stacy
    Division of Neurology, Duke University Medical Center, Durham, NC 27705, USA
    Neurology 70:2233-40. 2008
    ..The safety and efficacy of istradefylline, a selective adenosine A(2A) receptor antagonist, was evaluated in a 12-week, double-blind study in levodopa-treated Parkinson disease (PD) subjects with motor complications...
  6. doi request reprint Nonmotor symptoms in Parkinson's disease
    Mark Stacy
    Department of Neurology, Duke University Medical Center, Durham, North Carolina 27705, USA
    Int J Neurosci 121:9-17. 2011
    ..Symptoms attributed to the brainstem comprise depression, anxiety, and sleep disorders. Peripheral nervous system disturbances may lead to orthostatic hypotension, constipation, pain, and sensory disturbances...
  7. ncbi request reprint Apomorphine for the acute treatment of "off" episodes in Parkinson's disease
    Mark Stacy
    Division of Neurology, Duke University, 932 Morreene Road, MS 3333, Durham, NC27705, USA
    Parkinsonism Relat Disord 14:85-92. 2008
    ..Thus, clinical trial data support the efficacy of intermittent subcutaneous apomorphine as a rapid acute treatment for "off" episodes in advanced PD...
  8. ncbi request reprint Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment
    Mark Stacy
    Duke University Medical Center, 932 Morreene Road, Durham, NC 27705, USA
    Mov Disord 20:726-33. 2005
    ..The mean number of wearing-off symptoms reported by the 165 subjects indicating wearing-off on the clinical survey was 6.25, with tremor being the most common motor feature and tiredness the most common nonmotor feature...
  9. ncbi request reprint End-of-dose wearing off in Parkinson disease: a 9-question survey assessment
    Mark Stacy
    Division of Neurology, Duke University Medical School, Durham, North Carolina 27705, USA
    Clin Neuropharmacol 29:312-21. 2006
    ..No statistical differences were noted with respect to sex, UPDRS subsection scores, Schwab & England Scale, or Hoehn & Yahr Scale...
  10. ncbi request reprint Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson's disease
    M Stacy
    Duke University Medical Center, Durham, North Carolina 27705, USA
    J Neural Transm 114:211-7. 2007
    ..In the previous study we used a WOQ of 32 symptoms; however this tool was not designed for daily use. In this paper we describe the retrospective development of a simpler, 19-symptom WOQ more suitable for routine clinical use...
  11. ncbi request reprint Genome-wide scan for Parkinson's disease: the GenePD Study
    A L DeStefano
    Department of Neurology, Boston University Schools of Medicine and of Public Health, Boston, MA 02118, USA
    Neurology 57:1124-6. 2001
    ..The chromosome 9 region overlaps the genes for dopamine beta-hydroxylase and torsion dystonia. Although no strong evidence for linkage was found for any locus, these results may be of value in comparison with similar studies by others...
  12. ncbi request reprint Apomorphine: North American clinical experience
    Mark Stacy
    Movement Disorders Program, Duke University, Durham, North Carolina 27705, USA
    Neurology 62:S18-21. 2004
    ..Serious adverse events occurred in 16% of the subjects in these studies with the most common adverse events including dyskinesias (21%), hallucinations (11%), and orthostatic hypotension (9%)...
  13. doi request reprint Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia
    Mark Stacy
    Division of Neurology, Duke University Medical Center, Durham, North Carolina 27705, USA
    Clin Neuropharmacol 31:51-6. 2008
    ..In the long-term management of PD, treatment-associated dyskinesia often becomes sufficiently troublesome as to compromise the effective dosing of antiparkinsonian medication. More effective strategies for managing dyskinesia are needed...
  14. ncbi request reprint Epidemiology, clinical presentation, and diagnosis of cervical dystonia
    Mark Stacy
    Duke University Medical Center, 932 Morreene Road, Durham, NC 27705, USA
    Neurol Clin 26:23-42. 2008
  15. doi request reprint Medical treatment of Parkinson disease
    Mark Stacy
    Division of Neurology, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA
    Neurol Clin 27:605-31, v. 2009
    ..Patients may also develop autonomic dysfunction, cognitive changes, psychiatric symptoms, sensory complaints, and sleep disturbances. The treatment of motor and non-motor symptoms of Parkinson disease is addressed in this article...
  16. ncbi request reprint Management of impulse control disorders in Parkinson's disease
    Wendy R Galpern
    Mark Stacy, MD Duke University Medical Center, Division of Neurology, 932 Morreene Road, MS 3333, Durham, NC 27705, USA
    Curr Treat Options Neurol 9:189-97. 2007
    ..However, the management of each patient must be tailored for the particular clinical setting, and the development of evidence-based treatment strategies awaits future prospective studies and randomized controlled trials...
  17. ncbi request reprint Apomorphine in the treatment of Parkinson's disease
    Rukmini Menon
    Duke University Medical Center, Durham, NC 27705, USA
    Expert Opin Pharmacother 8:1941-50. 2007
    ..In this article, the authors review the historical background, structure, mechanism of action, pharmacologic properties, clinical trials, indications and side effects, as well as avenues of further research, of apomorphine...
  18. ncbi request reprint Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease
    Brad J Kolls
    Division of Neurology, Duke University Medical School, Durham, NC 27705, USA
    Clin Neuropharmacol 29:292-301. 2006
    ..This article reviews the pharmacology of apomorphine, the clinical data that support its use and suggest dosing and methods for initiating therapy in this challenging population of patients with Parkinson disease...
  19. pmc Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease
    David K Simon
    Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    BMC Med Genet 11:53. 2010
    ..We investigated the potential contribution of mtDNA variants or mutations to the risk of PD...
  20. doi request reprint Optimizing long-term therapy for Parkinson disease: options for treatment-associated dyskinesia
    Mark Stacy
    Division of Neurology, Duke University Medical Center, Durham, NC 27705, USA
    Clin Neuropharmacol 31:120-5. 2008
    ..In patients with advanced Parkinson disease, it is often not possible to induce periods of good mobility without dyskinesia...
  21. ncbi request reprint Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study
    Samer Karamohamed
    Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA
    Mov Disord 20:1188-91. 2005
    ..None of the variants were found in the GenePD families. Our results suggest that other variants or genes account for the familial risk of PD within the GenePD study...
  22. doi request reprint Clinical features of patients with blepharospasm: a report of 240 patients
    E L Peckham
    Department of Neurology, Neurology Specialists of Dallas, Dallas, TX 7523, USA
    Eur J Neurol 18:382-6. 2011
    ..To characterize patients with benign essential blepharospasm (BEB) by diagnosis, environmental risk factors, and family history...
  23. doi request reprint Extraocular muscle dystonia due to acquired (non-Wilsonian) hepatocerebral degeneration
    Joseph Ferrara
    Department of Medicine, Division of Neurology, Duke University Medical Center, Durham, North Carolina, USA
    Mov Disord 23:875-8. 2008
    ..This case illustrates that AHD should be considered in the differential diagnosis of extraocular muscle dystonia...
  24. ncbi request reprint Medical management of levodopa-associated motor complications in patients with Parkinson's disease
    Joseph Jankovic
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas 77030, USA
    CNS Drugs 21:677-92. 2007
    ....
  25. ncbi request reprint Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14620, USA
    Mov Disord 22:1061-8. 2007
    ..These criteria require validation and may be refined, but form a starting point for studies of the epidemiology and pathophysiology of PDPsy, and are a potential indication for therapy development...
  26. ncbi request reprint Other formulations and future considerations for apomorphine for subcutaneous injection therapy
    William Koller
    Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA
    Neurology 62:S22-6. 2004
    ..Although the diagnostic confirmation potential of this agent has been questioned, the drug may have an important role in evaluating the potential for benefit in the deep brain stimulation surgical setting...
  27. ncbi request reprint Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial
    Robert G Holloway
    Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
    Arch Neurol 61:1044-53. 2004
    ..The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear...
  28. ncbi request reprint Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease
    Anthony E Lang
    Toronto Western Hospital, University of Toronto, Ontario, Canada
    Ann Neurol 59:459-66. 2006
    ..This randomized controlled clinical trial was designed to confirm initial clinical benefits observed in a small, open-label trial using intraputamenal (Ipu) infusion of recombinant human GDNF (liatermin)...
  29. pmc PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study
    Anita L Destefano
    Department of Neurology, Boston University Schools of Medicine and of Public Health, Boston, MA 02118, USA
    Am J Hum Genet 70:1089-95. 2002
    ....
  30. ncbi request reprint Sleep disorders in Parkinson's disease: epidemiology and management
    Mark Stacy
    Muhammad Ali Parkinson Research Center, Barrow Neurological Institute, Phoenix, Arizona 85013, USA
    Drugs Aging 19:733-9. 2002
    ..If sleep attacks are suspected, it is reasonable to strongly caution patients regarding potentially risk-associated activities such as driving, and to consider careful withdrawal of dopaminergic therapy...
  31. ncbi request reprint Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors
    J N Joyce
    Thomas H Christopher Center for Parkinson s Disease Research, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Brain Res 955:138-52. 2002
    ..Thus, loss of dopamine D(3) receptors may be a more important contributing factor to a loss of response to dopaminergic drugs than changes in the D(2) receptor...
  32. pmc Serum urate as a predictor of clinical and radiographic progression in Parkinson disease
    Michael A Schwarzschild
    MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, USA
    Arch Neurol 65:716-23. 2008
    ..To determine whether concentration of serum urate, a purine metabolite and potent antioxidant that has been linked to a reduced risk of Parkinson disease (PD), predicts prognosis in PD...
  33. ncbi request reprint Impulse-control disorders in Parkinson's disease
    Joseph M Ferrara
    Baylor College of Medicine, Houston, TX, USA
    CNS Spectr 13:690-8. 2008
    ..This article reviews the anatomic substrates, behavioral spectrum, associated factors, and potential treatments for dopamine-replacement therapy-related compulsions in Parkinson's disease...
  34. ncbi request reprint The value of post-marketing medication surveys in Parkinson's disease
    Mark Stacy
    Curr Med Res Opin 20:113-4. 2004
  35. ncbi request reprint GDNF in treatment of Parkinson's disease: response to editorial
    Anthony E Lang
    Lancet Neurol 5:200-2. 2006